NASDAQ:PETX - Aratana Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.23 +0.12 (+2.35 %)
(As of 08/21/2018 04:00 PM ET)
Previous Close$5.11
Today's Range$5.02 - $5.26
52-Week Range$3.67 - $7.28
Volume249,891 shs
Average Volume393,410 shs
Market Capitalization$241.69 million
P/E Ratio-5.38
Dividend YieldN/A
Aratana Therapeutics logoAratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics. The company markets ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs. Its licensed products include canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States; AT-003, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats and dogs; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-017, a listeria based antigen delivery system for treating canine lymphoma in dogs; AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications; and AT-008, a therapeutic candidate for treating canine lymphoma in dogs in Europe. In addition, the company develops other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Receive PETX News and Ratings via Email

Sign-up to receive the latest news and ratings for PETX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.09
Current Ratio3.02
Quick Ratio2.44


Trailing P/E Ratio-5.38
Forward P/E Ratio-10.90
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.57 million
Price / Sales9.75
Cash FlowN/A
Price / CashN/A
Book Value$1.86 per share
Price / Book2.81


EPS (Most Recent Fiscal Year)($0.97)
Net Income$-47,510,000.00
Net Margins-154.23%
Return on Equity-35.25%
Return on Assets-23.57%


Outstanding Shares47,670,000
Market Cap$241.69 million

Aratana Therapeutics (NASDAQ:PETX) Frequently Asked Questions

What is Aratana Therapeutics' stock symbol?

Aratana Therapeutics trades on the NASDAQ under the ticker symbol "PETX."

How were Aratana Therapeutics' earnings last quarter?

Aratana Therapeutics Inc (NASDAQ:PETX) issued its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.19) by $0.05. The biopharmaceutical company had revenue of $4.91 million for the quarter, compared to analysts' expectations of $4.72 million. Aratana Therapeutics had a negative net margin of 154.23% and a negative return on equity of 35.25%. View Aratana Therapeutics' Earnings History.

When is Aratana Therapeutics' next earnings date?

Aratana Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Aratana Therapeutics.

What price target have analysts set for PETX?

6 equities research analysts have issued 12 month price targets for Aratana Therapeutics' shares. Their predictions range from $7.00 to $10.00. On average, they expect Aratana Therapeutics' stock price to reach $8.6667 in the next year. This suggests a possible upside of 66.0% from the stock's current price. View Analyst Price Targets for Aratana Therapeutics.

What is the consensus analysts' recommendation for Aratana Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aratana Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aratana Therapeutics.

What are Wall Street analysts saying about Aratana Therapeutics stock?

Here are some recent quotes from research analysts about Aratana Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. " (8/16/2018)
  • 2. HC Wainwright analysts commented, "Galliprant Approved in EU; Additional Product Approvals Expected in 2018; Reiterate Buy Galliprant approved for canine osteoarthritis in Europe. On January 11, Aratana announced that the EMA has granted Galliprant marketing approval for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Galliprant is licensed to Elanco, the animal health division of Eli Lilly (LLY; not rated), who has exclusive rights to commercialize the drug globally. Galliprant was first approved in the US in March 2016, and in the nine months ended September 30, 2017, generated approximately $9M in product sales and $4M in license and collaboration revenue for Aratana. Going forward, Elanco has assumed all development, regulatory and manufacturing responsibilities for Galliprant, and we expect the company to launch the drug in Europe in 2Q18." (1/16/2018)

Who are some of Aratana Therapeutics' key competitors?

Who are Aratana Therapeutics' key executives?

Aratana Therapeutics' management team includes the folowing people:
  • Dr. Steven St. Peter, Co-Founder, Pres, CEO & Director (Age 52)
  • Mr. Craig A. Tooman, CFO & Treasurer (Age 52)
  • Mr. Brent A. Standridge, Chief Operating Officer (Age 60)
  • Mr. John Paolucci, Director of Marketing
  • Dr. Ernst Heinen, Chief Devel. Officer (Age 55)

Has Aratana Therapeutics been receiving favorable news coverage?

Media stories about PETX stock have trended somewhat positive on Tuesday, according to Accern. The research firm rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.05 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 47.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Aratana Therapeutics.

Who are Aratana Therapeutics' major shareholders?

Aratana Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.02%), Massachusetts Financial Services Co. MA (2.94%), Dimensional Fund Advisors LP (1.91%), Grandeur Peak Global Advisors LLC (1.49%), Millennium Management LLC (1.12%) and Renaissance Technologies LLC (0.80%). Company insiders that own Aratana Therapeutics stock include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Institutional Ownership Trends for Aratana Therapeutics.

Which major investors are selling Aratana Therapeutics stock?

PETX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC and Sheaff Brock Investment Advisors LLC. Company insiders that have sold Aratana Therapeutics company stock in the last year include Brent Standridge, Craig A Tooman, Ernst Heinen, Healthcare Master Fun Broadfin and Peter Steven St. View Insider Buying and Selling for Aratana Therapeutics.

Which major investors are buying Aratana Therapeutics stock?

PETX stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, BlackRock Inc., Grandeur Peak Global Advisors LLC, Dimensional Fund Advisors LP, Acadian Asset Management LLC and American Century Companies Inc.. View Insider Buying and Selling for Aratana Therapeutics.

How do I buy shares of Aratana Therapeutics?

Shares of PETX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aratana Therapeutics' stock price today?

One share of PETX stock can currently be purchased for approximately $5.22.

How big of a company is Aratana Therapeutics?

Aratana Therapeutics has a market capitalization of $241.69 million and generates $25.57 million in revenue each year. The biopharmaceutical company earns $-47,510,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Aratana Therapeutics employs 85 workers across the globe.

How can I contact Aratana Therapeutics?

Aratana Therapeutics' mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company can be reached via phone at 913-353-1000 or via email at [email protected]

MarketBeat Community Rating for Aratana Therapeutics (NASDAQ PETX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  507
MarketBeat's community ratings are surveys of what our community members think about Aratana Therapeutics and other stocks. Vote "Outperform" if you believe PETX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PETX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel